This study is looking at how well a new medicine called JNJ-90301900 works when added to existing treatments for a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC). Patients with locally advanced, non-removable stage III NSCLC will first receive a combination of chemotherapy (a treatment using special drugs) and radiation therapy (using high-energy rays to kill cancer cells), known as cCRT. After that, they will receive consolidation immunotherapy (cIT), which helps the immune system fight cancer. The study will see if this combination improves the objective response rate (ORR), meaning how well the cancer responds to treatment.

• Study participation requires multiple visits for treatments and check-ups.
• There may be risks, including allergic reactions to the treatment.
• Compensation for participation is not mentioned.

To join, you must be diagnosed with NSCLC within the last 3 months and be able to get the standard treatment. Some health conditions, like heart problems or other cancers, may prevent you from joining. Always talk to your doctor about whether this study is right for you.